Cancer Research

Modern medical science laboratory
#Cancer research #High throughput screening #Oncology #SPT Labtech

SPT Labtech & BellBrook Labs collaborate on oncology 

SPT Labtech and BellBrook Labs are collaborating to advance cancer research, having developed a miniaturised, high-throughput screening platform for the discovery and profiling of Vacuolar protein sorting associated protein 4B (VPS4B) ATPase inhibitors.   VPS4B has emerged as a high-priority therapeutic target in oncology due to its overexpression in specific tumours and its… Read More

#Cancer Research #News

#Oncology #Syncona #The Francis Crick Institute

ALTx Therapeutics launched to develop novel cancer treatments 

Slingshot Therapeutics has launched ALTx Therapeutics with funding worth £12.55 million ($17.04 million) to develop novel treatments for cancer.  ALTx Therapeutics launched into the Slingshot accelerator with backing from Syncona, the Francis Crick Institute and Cancer Research Horizons.  Spinning out of the Crick, ALTx is focused on developing therapeutics targeting vulnerabilities… Read More

#Business & Investment #Cancer Research #News

The European Medicines Agency building
#CHMP #European Medicines Agency #Oncology

CHMP recommends combination therapy to treat anal cancer  

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer.  Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with… Read More

#Cancer Research #News

Immunotherapy
#Cancer immunotherapy #Clinical trial #Melanoma

Immunotherapy before surgery could better treat melanoma 

Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life.  New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.   Administering… Read More

#Cancer Research #News

#Advanced Therapies #Brain cancer #FDA #Gene therapy #Oncology #Phase I trial #Siren Biotechnology

FDA clears first cancer gene therapy for trials

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with… Read More

#Cancer Research #Editor's Choice #News #Regulatory

#Artificial intelligence (AI) #Colorectal cancer #KRAS #Oncology #Oxford Drug Design

Oxford Drug Design validates cancer therapeutic mechanism

AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More

#Cancer Research #News

Cancer cells
#Biomarkers #Breast cancer #Genetic profiling #HER2

Genetic markers drive breast cancer drug resistance, study shows 

Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant.  Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer.  The… Read More

#Cancer Research #News

Lab of the future
#Cancer #The University of Manchester #UK

New UK lab to accelerate cancer diagnostic solutions 

A new state-of-the-art lab has opened in the UK to accelerate the development of cancer diagnostic solutions.  Vortex Biotech has opened a new laboratory at Manchester Science Park, hoping to accelerate the development of cancer diagnostic solutions. The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product… Read More

#Cancer Research #News

Pancreatic cancer
#Oncology #Pancreatic cancer #Tokyo University of Science #Tumour microenvironment (TME)

Potential tumour-suppressing gene identified in pancreatic cancer

A new study has revealed that low levels of CTDNEP1 may drive early and deadly pancreatic tumours, highlighting its role as a tumour suppressor.  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for… Read More

#Cancer Research #News

Ovarian cancer cells
#Corcept Therapeutics #Oncology #Ovarian cancer #Phase III trial

Ovarian cancer drug reduces risk of death by 35%

Corcept Therapeutics has announced that ROSELLA, the company’s Phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint.  In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of… Read More

#Cancer Research #Editor's Choice #News

#Bristol Myers Squibb #Collaboration #Janux Therapeutics #Oncology #Solid tumours

Janux and Bristol Myers Squibb partner on tumour-activated therapeutic

Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement.   Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types.  Janux… Read More

#Business & Investment #Cancer Research #News

X-ray showing colon cancer
#Bowel cancer #Colorectal cancer #Gene mutation #Oncology #University of Delaware

Researchers find common mutation sparks colon tumour growth

A team of researchers from ChristianaCare and the University of Delaware in the US has uncovered that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumours to form. … Read More

#Cancer Research #Editor's Choice #News

Desmoid tumour
#Financing #Oncology #Parabilis Medicines

Parabilis Medicines announces oversubscribed $305m financing

Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing.  The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a… Read More

#Business & Investment #Cancer Research #News

Colorectal cancer
#Colorectal cancer #Gene mutation #Tumour biology

Gene mutation accelerates tumour growth in colorectal cancer 

A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests.  A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More

#Cancer Research #News

Ovarian cancer cells
#CureLab Oncology #DNA #Oncology #Ovarian cancer

Therapy could increase ovarian cancer survival, paper finds 

A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals.  A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More

#Cancer Research #News

#Cancer research #RNA #Storm Therapeutics

Biotech companies to develop epitranscriptomic cancer therapies 

Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications.  STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition.   Post-transcriptional modification of RNA, including N6-methyladenosine… Read More

#Business & Investment #Cancer Research #News